Literature DB >> 15761972

Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw.

Hui Dong1, Fu-Er Lu, Zhi-Qiang Gao, Li-Jun Xu, Kai-Fu Wang, Xin Zou.   

Abstract

AIM: To investigate the effects of emodin on the treatment of non-alcoholic fatty liver in rats induced by high caloric laboratory chaw.
METHODS: Non-alcoholic fatty liver model was successfully established by feeding with high caloric laboratory chaw for 12 wk. Then the model rats were randomly divided into 3 groups, namely model control group, emodin group and dietary treatment group. The rats in emodin group were given emodin at dose of 40 mg/(kg x d) while animals in other groups were given distilled water of the same volume. The rats in model control group were fed with high caloric laboratory chaw while animals in other groups were fed with normal diet. Four weeks later, liver index (liver/body weight ratio), serum activities of liver-associated enzymes, blood lipid, fasting blood glucose, fasting plasma insulin, HOMA insulin resistance index (HOMA-IR), hepatic triglyceride content and histology features of all groups were assayed. The expression of hepatic peroxisomal proliferator activated receptor (PPAR) gamma was determined by RT-PCR.
RESULTS: The body weight, liver index, serum activities of alanine aminotransferase (ALT), blood lipid, hepatic triglyceride content of model control group were significantly elevated, with moderate to severe hepatocyte steatosis. The expression of hepatic PPAR gamma mRNA was obviously reduced in model control group. Compared with model control group, the body weight, liver index, serum activities of ALT, blood lipids and hepatic triglyceride of emodin group significantly decreased and hepatic histology display was also greatly improved. Meanwhile, the expression of hepatic PPAR gamma mRNA was elevated. However, high serum activities of ALT and hyperlipidemia were persisted in dietary treatment group although liver index was decreased and liver histology was somewhat improved.
CONCLUSION: It is suggested that emodin might be effective in the treatment of non-alcoholic fatty liver in rats. Its therapeutic mechanism could be associated with increasing the expression of hepatic PPAR gamma mRNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761972      PMCID: PMC4250681          DOI: 10.3748/wjg.v11.i9.1339

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  [Effect of emodin on development of hepatic fibrosis in rats].

Authors:  Y Zhan; D Li; H Wei
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2000-04

Review 2.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

3.  Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.

Authors:  J E Lavine
Journal:  J Pediatr       Date:  2000-06       Impact factor: 4.406

4.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

5.  Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein.

Authors:  Jihong Han; David P Hajjar; Xiaoye Zhou; Antonio M Gotto; Andrew C Nicholson
Journal:  J Biol Chem       Date:  2002-04-12       Impact factor: 5.157

6.  Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation.

Authors:  S C Lu; L Alvarez; Z Z Huang; L Chen; W An; F J Corrales; M A Avila; G Kanel; J M Mato
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

7.  Hepatic effects of dietary weight loss in morbidly obese subjects.

Authors:  T Andersen; C Gluud; M B Franzmann; P Christoffersen
Journal:  J Hepatol       Date:  1991-03       Impact factor: 25.083

8.  Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.

Authors:  M F Abdelmalek; P Angulo; R A Jorgensen; P B Sylvestre; K D Lindor
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

9.  Effects of low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.

Authors:  Jian-Gao Fan; Lan Zhong; Zheng-Jie Xu; Li-Yan Tia; Xiao-Dong Ding; Min-Sheng Li; Guo-Liang Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

10.  Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury.

Authors:  A M Diehl; Z Goodman; K G Ishak
Journal:  Gastroenterology       Date:  1988-10       Impact factor: 22.682

View more
  11 in total

Review 1.  Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease.

Authors:  Hui Dong; Fu-Er Lu; Li Zhao
Journal:  Chin J Integr Med       Date:  2012-02-05       Impact factor: 1.978

2.  Application of proton magnetic resonance spectroscopy and computerized tomography in the diagnosis and treatment of nonalcoholic fatty liver disease.

Authors:  Nan Wang; Hui Dong; Shichao Wei; Fuer Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-06-19

3.  Emodin attenuates systemic and liver inflammation in hyperlipidemic mice administrated with lipopolysaccharides.

Authors:  Xuemei Jia; Stephen Iwanowycz; Junfeng Wang; Fatma Saaoud; Fang Yu; Yuzhen Wang; Jun Hu; Saurabh Chatterjee; Qian Wang; Daping Fan
Journal:  Exp Biol Med (Maywood)       Date:  2014-04-16

4.  A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis.

Authors:  Hong-Liang Liang; Qin Ouyang
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

5.  Emodin prevents intrahepatic fat accumulation, inflammation and redox status imbalance during diet-induced hepatosteatosis in rats.

Authors:  Anna Alisi; Anna Pastore; Sara Ceccarelli; Nadia Panera; Daniela Gnani; Giovannella Bruscalupi; Mara Massimi; Giulia Tozzi; Fiorella Piemonte; Valerio Nobili
Journal:  Int J Mol Sci       Date:  2012-02-20       Impact factor: 6.208

6.  Emodin, a Naturally Occurring Anthraquinone Derivative, Ameliorates Dyslipidemia by Activating AMP-Activated Protein Kinase in High-Fat-Diet-Fed Rats.

Authors:  Thing-Fong Tzeng; Hung-Jen Lu; Shorong-Shii Liou; Chia Ju Chang; I-Min Liu
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-10       Impact factor: 2.629

7.  Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats.

Authors:  Raghdaa Hamdan Al Zarzour; Mariam Ahmad; Mohd Zaini Asmawi; Gurjeet Kaur; Mohammed Ali Ahmed Saeed; Majed Ahmed Al-Mansoub; Sultan Ayesh Mohammed Saghir; Nasiba Salisu Usman; Dhamraa W Al-Dulaimi; Mun Fei Yam
Journal:  Nutrients       Date:  2017-07-18       Impact factor: 5.717

Review 8.  A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix.

Authors:  Mengting Zhou; Naihua Hu; Meichen Liu; Ying Deng; Linfeng He; Chaocheng Guo; Xingtao Zhao; Yunxia Li
Journal:  Biomed Res Int       Date:  2020-04-20       Impact factor: 3.411

9.  Genistein Attenuates Nonalcoholic Steatohepatitis and Increases Hepatic PPARγ in a Rat Model.

Authors:  Warinda Susutlertpanya; Duangporn Werawatganon; Prasong Siriviriyakul; Naruemon Klaikeaw
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-13       Impact factor: 2.629

10.  Maotai ameliorates diethylnitrosamine-initiated hepatocellular carcinoma formation in mice.

Authors:  Xu Yi; Li Long; Chunzhang Yang; Yingying Lu; Mingliang Cheng
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.